Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience

NCT06520826 is registered in ClinicalTrials.gov with USRC Kidney Research as lead sponsor.

NCT NCT06520826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06520826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects: Vafseo Outcomes In-Center Experience
Lead sponsor
USRC Kidney Research
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 20, 2024
Completion date
June 30, 2026
Enrollment
2,200 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anemia of chronic kidney disease